Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 7300 | 7.3 |
09:34 ET | 2835 | 7.28 |
09:36 ET | 100 | 7.24 |
09:38 ET | 1271 | 7.2259 |
09:39 ET | 1090 | 7.195 |
09:43 ET | 856 | 7.19 |
09:45 ET | 100 | 7.185 |
09:48 ET | 2900 | 7.15 |
09:50 ET | 1788 | 7.19 |
09:54 ET | 8596 | 7.21 |
09:56 ET | 100 | 7.31 |
09:57 ET | 1296 | 7.29 |
09:59 ET | 100 | 7.215 |
10:01 ET | 475 | 7.28 |
10:03 ET | 332 | 7.29 |
10:08 ET | 700 | 7.25 |
10:12 ET | 3258 | 7.35 |
10:14 ET | 9600 | 7.35 |
10:15 ET | 1452 | 7.3959 |
10:17 ET | 100 | 7.4 |
10:19 ET | 200 | 7.35 |
10:21 ET | 100 | 7.375 |
10:24 ET | 3155 | 7.27 |
10:26 ET | 2500 | 7.285 |
10:35 ET | 200 | 7.21 |
10:39 ET | 1760 | 7.24 |
10:42 ET | 500 | 7.3099 |
10:44 ET | 288 | 7.27 |
10:46 ET | 6680 | 7.26 |
10:48 ET | 100 | 7.21 |
10:50 ET | 2800 | 7.195 |
10:51 ET | 1445 | 7.18 |
10:53 ET | 157 | 7.17 |
10:57 ET | 1000 | 7.17 |
11:00 ET | 200 | 7.1101 |
11:02 ET | 450 | 7.17 |
11:09 ET | 26736 | 7.13 |
11:13 ET | 100 | 7.1 |
11:22 ET | 483 | 7.1 |
11:26 ET | 425 | 7.19 |
11:27 ET | 188 | 7.13 |
11:29 ET | 252 | 7.1305 |
11:33 ET | 1500 | 7.06 |
11:36 ET | 520 | 7.07 |
11:38 ET | 1100 | 7.04 |
11:40 ET | 200 | 7.065 |
11:42 ET | 716 | 7.06 |
11:44 ET | 296 | 7.055 |
11:45 ET | 450 | 7.07 |
11:47 ET | 587 | 7.05 |
11:49 ET | 1243 | 7.08 |
11:56 ET | 250 | 7.105 |
11:58 ET | 11637 | 7.145 |
12:00 ET | 5034 | 7.13 |
12:05 ET | 200 | 7.15 |
12:09 ET | 250 | 7.185 |
12:12 ET | 1019 | 7.2 |
12:14 ET | 500 | 7.2 |
12:18 ET | 100 | 7.17 |
12:20 ET | 1100 | 7.1799 |
12:23 ET | 1402 | 7.22 |
12:27 ET | 160 | 7.21 |
12:30 ET | 551 | 7.2 |
12:32 ET | 400 | 7.2 |
12:36 ET | 7280 | 7.12 |
12:38 ET | 140 | 7.15 |
12:39 ET | 140 | 7.1999 |
12:41 ET | 600 | 7.17 |
12:50 ET | 1125 | 7.1227 |
12:52 ET | 1200 | 7.13 |
12:54 ET | 110 | 7.15 |
12:57 ET | 900 | 7.21 |
12:59 ET | 3400 | 7.1901 |
01:01 ET | 1502 | 7.19 |
01:03 ET | 1910 | 7.1901 |
01:14 ET | 1040 | 7.2751 |
01:15 ET | 9176 | 7.26 |
01:17 ET | 1168 | 7.2364 |
01:26 ET | 1572 | 7.1703 |
01:30 ET | 1647 | 7.15 |
01:32 ET | 16389 | 7.16 |
01:33 ET | 250 | 7.2 |
01:37 ET | 100 | 7.13 |
01:39 ET | 2923 | 7.08 |
01:42 ET | 150 | 7.1 |
01:44 ET | 1214 | 7.11 |
01:46 ET | 660 | 7.11 |
01:48 ET | 950 | 7.175 |
01:53 ET | 500 | 7.18 |
02:00 ET | 1300 | 7.17 |
02:02 ET | 100 | 7.2 |
02:06 ET | 502 | 7.215 |
02:11 ET | 600 | 7.23 |
02:15 ET | 100 | 7.27 |
02:22 ET | 2115 | 7.22 |
02:27 ET | 200 | 7.235 |
02:33 ET | 200 | 7.27 |
02:38 ET | 412 | 7.245 |
02:40 ET | 1364 | 7.22 |
02:42 ET | 1200 | 7.21 |
02:44 ET | 215 | 7.205 |
02:58 ET | 850 | 7.23 |
03:00 ET | 950 | 7.22 |
03:02 ET | 600 | 7.22 |
03:07 ET | 1735 | 7.24 |
03:12 ET | 406 | 7.23 |
03:14 ET | 100 | 7.2 |
03:16 ET | 447 | 7.24 |
03:20 ET | 1300 | 7.235 |
03:21 ET | 500 | 7.24 |
03:23 ET | 17368 | 7.16 |
03:25 ET | 200 | 7.14 |
03:27 ET | 2552 | 7.1725 |
03:32 ET | 1204 | 7.2 |
03:34 ET | 1908 | 7.205 |
03:36 ET | 4005 | 7.23 |
03:38 ET | 600 | 7.23 |
03:39 ET | 2546 | 7.23 |
03:41 ET | 2374 | 7.19 |
03:43 ET | 796 | 7.185 |
03:45 ET | 2706 | 7.18 |
03:48 ET | 1500 | 7.21 |
03:50 ET | 2222 | 7.22 |
03:52 ET | 2842 | 7.28 |
03:54 ET | 3378 | 7.3288 |
03:56 ET | 5935 | 7.28 |
03:57 ET | 5176 | 7.3 |
03:59 ET | 11439 | 7.22 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 214.8M | -5.6x | --- |
Prelude Therapeutics Inc | 215.9M | -2.1x | --- |
Aldeyra Therapeutics Inc | 218.6M | -7.2x | --- |
Pyxis Oncology Inc | 215.5M | -2.6x | --- |
Acrivon Therapeutics Inc | 212.4M | -2.4x | --- |
Design Therapeutics Inc | 215.8M | -3.7x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $214.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.